• Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business Officer
  • Charles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s financial operations, following Jeffrey Rona’s transition to an advisory role
  • Eliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric medicines
  • Victoria Fort promoted to Chief Strategy Officer, reflecting her leadership in advancing Ovid’s corporate strategy and investor relations

NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced several strategic appointments strengthening its executive leadership team to support the Company’s next phase of development.

Kevin Norrett, MS, MBA, will join Ovid as Chief Business Officer to spearhead business and corporate development functions as well as strategic partnerships. Charles Carter, MS, MBA, was promoted to Chief Financial Officer, and will lead business and financial operations. Charles succeeds Jeffrey Rona, who will remain a long-term advisor to the Company through 2027 to ensure a smooth operational transition. Building on his prior role as an advisor to the Company, Eliseo Salinas, MD, MSc, has joined as Executive R&D Advisor, providing strategic and operational guidance for the Company’s research and development programs. Victoria Fort was promoted to Chief Strategy Officer, leading enterprise strategy, investor relations, and operational growth initiatives.